Key Financial Performance - Standalone (Q1 FY27 vs Q1 FY26)
Income Statement Highlights (₹ in lacs):
- Revenue from Operations: ₹4,230.94 (vs ₹2,917.64 in Q1 FY26) - growth of 45.01%
- EBITDA: ₹501.12 (vs ₹413.06) - growth of 21.32%
- Other Income: ₹41.85 (vs ₹77.34) - decline of 45.89%
- Finance Cost: ₹100.82 (vs ₹85.14) - increase of 18.42%
- Depreciation and amortization: ₹200.96 (vs ₹211.18) - decline of 4.84%
- Net Profit after tax: ₹199.33 (vs ₹116.74) - growth of 70.75%
Key Metrics:
- Net Total Income: ₹4,272.79 - growth of 42.67%
- Net Profit: ₹210.01 - growth of 159.04%
- EBITDA margin: 11.84% (vs 14.16% in Q1 FY26)
Key Financial Performance - Consolidated (Q1 FY27 vs Q1 FY26)
Income Statement Highlights (₹ in lacs):
- Revenue from Operations: ₹4,230.94 (vs ₹3,302.54 in Q1 FY26) - growth of 28.11%
- EBITDA: ₹496.57 (vs ₹431.73) - growth of 15.02%
- Other Income: ₹41.85 (vs ₹63.09) - decline of 33.67%
- Finance Cost: ₹100.81 (vs ₹85.38) - increase of 18.07%
- Depreciation and amortization: ₹200.96 (vs ₹211.18) - decline of 4.84%
- Net Profit after tax: ₹194.80 (vs ₹135.17) - growth of 44.11%
Key Metrics:
- Net Total Income: ₹4,272.79 - growth of 26.95%
- Net Profit: ₹204.66 - growth of 105.44%
- EBITDA margin: 11.74% (vs 13.07% in Q1 FY26)
Revenue Breakdown Analysis (₹ in lacs)
Domestic Sales:
- Branded Formulation: ₹737.67 (vs ₹454.58) - growth of 62.27%
- Branded Veterinary: ₹587.35 (vs ₹296.90) - growth of 97.83%
- P2P: ₹1,327.09 (vs ₹1,536.69) - decline of 13.64%
- Total Domestic Sales: ₹2,652.11 (vs ₹2,288.17) - growth of 15.91%
Export Sales:
- Branded Formulation: ₹1,483.42 (vs ₹882.85) - growth of 68.03%
- Total Export Sales: ₹1,483.42 (vs ₹882.85)
Other Income:
- Other Operating Income: ₹95.41 (vs ₹131.52) - decline of 27.46%
- Other Income: ₹41.85 (vs ₹63.09) - decline of 33.67%
Total Consolidated Revenue:
- Revenue from Operations: ₹4,230.94 (vs ₹3,302.54)
- Net Total Income: ₹4,272.79 (vs ₹3,365.63) - growth of 26.95%
Company Business Description
Lyka Labs Limited is engaged in manufacturing and marketing of finished formulations for human and animal healthcare across various therapeutic segments.